Stock listing
APUS Stock Price, News, Filings & Events — Apimeds Pharmaceuticals Us, Inc.
Selected listing: APUS · BOATS · USD · US
This page tracks Apimeds Pharmaceuticals Us, Inc.'s APUS:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following APUS:BOATS. APUS:BOATS is the stock-level entry point for investors researching Apimeds Pharmaceuticals Us, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Apimeds Pharmaceuticals Us, Inc. (ticker: APUS) is a public company operating in the American market. With a market capitalization of approximately $98.6 million, the company focuses on developing pharmaceutical products. Investors can find relevant information about its operations and performance on its dedicated public company page.

- Ticker
- APUS:BOATS
- Asset type
- Stock
- Market cap
- $3.2M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Apimeds Pharmaceuticals Us, Inc. APUS:BOATS stock context
This page tracks Apimeds Pharmaceuticals Us, Inc.'s APUS:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following APUS:BOATS. APUS:BOATS is the stock-level entry point for investors researching Apimeds Pharmaceuticals Us, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Apimeds Pharmaceuticals Us, Inc. (ticker: APUS) is a public company operating in the American market. With a market capitalization of approximately $98.6 million, the company focuses on developing pharmaceutical products. Investors can find relevant information about its operations and performance on its dedicated public company page.
Latest news from Apimeds Pharmaceuticals Us, Inc.
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Pu...
September 14, 2026
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advan...
May 5, 2026
Apimeds Pharmaceuticals US : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
May 4, 2026
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Fil...
March 24, 2026
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
February 11, 2026
Research Apimeds Pharmaceuticals Us, Inc.
Apimeds Pharmaceuticals Us, Inc. investor report
Review AI stock analysis and investor report context for APUS:BOATS.
Apimeds Pharmaceuticals Us, Inc. company profile
View the public company page for Apimeds Pharmaceuticals Us, Inc. on 6ix.
Apimeds Pharmaceuticals Us, Inc. news
Read company news and market updates connected to Apimeds Pharmaceuticals Us, Inc..
Apimeds Pharmaceuticals Us, Inc. investor events
Find investor webinars, events, and replay context for Apimeds Pharmaceuticals Us, Inc..